Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

12.03 +0.29 (+2.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 366,161
Open 11.61
Bid (Size) 11.01 (1)
Ask (Size) 12.29 (5)
Prev. Close 11.74
Today's Range 11.33 - 12.45
52wk Range 9.080 - 39.00
Shares Outstanding 27,985,145
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioXcel Therapeutics: Q1 Earnings Insights
BioXcel Therapeutics (NASDAQ:BTAI) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Preview: BioXcel Therapeutics's Earnings
BioXcel Therapeutics (NASDAQ:BTAI) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that BioXcel... 
Via Benzinga

Performance

YTD
-47.31%
-47.31%
1 Month
-18.55%
-18.55%
3 Month
-31.61%
-31.61%
6 Month
-55.79%
-55.79%
1 Year
-61.26%
-61.26%

More News

Read More
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Via Benzinga
Oaktree, Qatar Investment Inject $260M In BioXcel To Fund Commercialization Of Schizophrenia Med
Via Benzinga
Earnings Scheduled For March 10, 2022
Via Benzinga
How To Attend BioXcel Therapeutics Q1 2022 Earnings Conference Call
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Via Benzinga
Looking Into Bioxcel Therapeutics Inc's Recent Short Interest
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 7, 2022: SDPR S&P 500, Houghton Mifflin, Sunshine Biopharma And More
Via Benzinga
4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why BioXcel Therapeutics Stock Is Surging Today
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Via Benzinga
Recap: BioXcel Therapeutics Q4 Earnings
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Via Benzinga
BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer
Via Benzinga
FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.